Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001437749-25-021447
Filing Date
2025-06-27
Accepted
2025-06-27 17:25:01
Documents
20
Period of Report
2025-08-18

Document Format Files

Seq Description Document Type Size
1 FORM PRE 14A mbrx20250623_pre14a.htm   iXBRL PRE 14A 876461
6 a01.jpg GRAPHIC 186317
7 a02.jpg GRAPHIC 204220
8 a03.jpg GRAPHIC 218367
9 moleculinnewlogoresized.jpg GRAPHIC 7783
  Complete submission text file 0001437749-25-021447.txt   3058694

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20241231.xsd EX-101.SCH 4575
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20241231_def.xml EX-101.DEF 1750
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20241231_lab.xml EX-101.LAB 1775
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20241231_pre.xml EX-101.PRE 714
22 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250623_pre14a_htm.xml XML 91912
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37758 | Film No.: 251088029
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)